Overview
Drug registration is the core legal procedure that turns a company's R&D output into a marketable product. In China, the Drug Administration Law and the Measures for the Administration of Drug Registration (2020 edition) established a registration system built around the marketing authorization holder (MAH) model. Registration approval determines not only whether and how quickly a product can launch, but also its valuation, financing prospects, VBP eligibility and competitive position.
We advise innovative drugs, improved new drugs, generics, biosimilars and traditional Chinese medicines on end-to-end registration strategy, helping clients find the best route in a demanding regulatory environment.
Registration classification system
Under the 2020 Measures, drugs are registered in three broad categories: chemical drugs, biologics and traditional Chinese medicine (TCM).
Chemical drug classes
- Class 1 (innovative drugs): new chemical entities not yet approved anywhere, with clear structure, pharmacological activity and clinical value.
- Class 2 (improved new drugs): modifications such as new routes of administration, new salt/base forms or new dosage forms.
- Class 3 (copy of a drug approved abroad but not in China): generics of originator drugs marketed overseas but not domestically.
- Class 4 (copy of a domestically approved drug): the traditional generic (ANDA) of an originator already marketed in China.
- Class 5 (approved abroad, not in China): importation of a drug already marketed overseas, whether originator or generic.
Biological product classes
- Preventive biologics (vaccines): innovative vaccines, improved vaccines and vaccines already marketed abroad.
- Therapeutic biologics: innovative biologics (monoclonal antibodies, ADCs, cell and gene therapies), improved biologics and biosimilars.
TCM classes
- Innovative TCM drugs: compound formulations and active ingredients extracted from single plant, animal or mineral sources.
- Improved TCM drugs: changes to route of administration, dosage form or indications.
- Classical formula preparations: TCM compound preparations managed under the classical formulas catalogue.
- Same-name same-formula drugs: products sharing a generic name, formula and dosage form with an approved TCM.
Key point: the registration class chosen dictates the review pathway, data requirements, review timelines and post-market exclusivity position. A wrong classification can derail an entire strategy at great cost in time and money. We recommend engaging legal and regulatory counsel at the project-planning stage to pre-judge classification and map the route.
The marketing authorization holder (MAH) system
Since the 2019 revision of the Drug Administration Law, China has fully implemented the MAH system — one of the most profound recent changes to its drug regulation.
Core legal meaning of the MAH system
- Holder eligibility: an MAH may be a manufacturer, a research institution or other non-manufacturing entity. The holder bears lifecycle liability for the drug's safety, efficacy and quality controllability.
- Separation of holding and manufacturing: a holder may manufacture itself or contract manufacturing to a third party, opening the market to R&D-led companies without their own facilities.
- Lifecycle liability: the holder is responsible from R&D through registration, manufacture, sale and post-market study to adverse-reaction monitoring, and cannot shed that responsibility by delegating.
- Change management: changes to holder name, registered address, manufacturing site, formula or process require a supplementary application or filing.
Our MAH services
- MAH eligibility assessment and application strategy
- Structuring and negotiating contract-manufacturing agreements
- Drafting quality agreements between MAH and CMO
- Cross-province MAH regulatory coordination
- Registration procedures and documents for MAH transfers, divisions and mergers
- MAH annual-report compliance
- Arranging domestic agents / representatives for foreign MAHs
IND application
The Investigational New Drug (IND) application is the first administrative gate for an innovative drug entering clinical development.
Core legal requirements
- Application materials: CMC information, non-clinical (pharmacology/toxicology) data, the trial protocol and the investigator's brochure.
- Implied-consent system: if the Center for Drug Evaluation (CDE) raises no objection within 60 working days of acceptance, the applicant may proceed with the submitted protocol — a major shift from approval to "tacit consent" in 2019.
- Prior ethics review: the protocol must first be approved by the trial site's ethics committee.
- Communication channels: applicants may use Type A/B/C meetings with CDE on key technical issues.
Common IND legal risks
- Data integrity: authenticity and integrity of non-clinical data (especially outsourced to CROs) is a CDE priority; falsification leads to rejection and a 3-year bar on re-application.
- False patent declarations: a false patent-status statement in an IND may constitute fraud and trigger downstream patent disputes.
- Ethics compliance: subjects may not be recruited before the IND tacit-consent period lapses.
NDA / BLA application
The New Drug Application (NDA) — or Biologics License Application (BLA) — is the final and most critical review before market access.
Key legal and technical points
- Complete data package: CMC, non-clinical and clinical (Phases I–III) modules; CDE has required eCTD format since 2024.
- Process validation: the submitted process must be commercially scalable and consistent with registration and clinical batches; process changes need bridging studies.
- Labelling: indications, dosage, adverse reactions and contraindications must rest on adequate clinical evidence; off-label wording is scrutinised.
- Review timelines: a nominal 200 working days (120 technical review + 80 formal/administrative), though in practice longer.
Pre-approval inspection (PAI) support
- Mock self-inspection and gap analysis before the inspection
- Inspection-response planning and data-integrity pre-assessment
- Protection of legal rights during the inspection
- Remediation and reply strategy for defects found
Accelerated registration pathways
China offers four accelerated pathways. Matching the right one to your product can dramatically shorten review times.
Breakthrough therapy designation
- Scope: drugs for serious or life-threatening diseases showing clear early clinical superiority over existing treatments.
- Timing: typically applied during Phase I or II.
- Benefits: close CDE guidance and priority on resources; may qualify for conditional approval and priority review.
- Obligations: concealing later negative data or safety issues carries serious consequences.
Conditional approval
- Scope: drugs for serious life-threatening diseases with no effective treatment, or urgently needed for public health, where early data predict clinical value.
- Standard: approval based on surrogate endpoints or early-phase data without full Phase III.
- Post-market obligations (the key risk): the holder must complete confirmatory post-marketing trials within a set period. Failure to do so — or a confirmatory trial that fails — leads to revocation of the registration certificate even after the product has been selling. This is the biggest compliance risk of conditional approval.
- Our role: feasibility assessment, compliance review of confirmatory study design, and negotiation of endpoints and timelines with CDE.
Priority review
- Scope: drugs in clinical shortage, innovative drugs for major infectious and rare diseases, paediatric new drugs/forms/specs, and urgently needed vaccines.
- Timeline: review shortened to 130 working days (vs. 200 generally).
- Relationship to conditional approval: the two may overlap but are independent procedures.
Special approval
- Scope: in public-health emergencies, drugs urgently needed with no effective treatment.
- Features: unified command, early intervention, rapid review. During COVID-19 this enabled rapid approval of several vaccines and treatments.
Practical tip: the four pathways overlap and stack. A rare-disease innovative drug may qualify for breakthrough, conditional and priority review at once — but each has different application timing and evidence thresholds. Choose based on development stage and data maturity; a mis-step can forfeit a valuable acceleration.
ANDA application (generics)
Generics (and biosimilars) are central to China's market, and under VBP the competition is intense. Registration strategy directly affects first-generic status, exclusivity and VBP eligibility.
Core legal issues
- Reference listed drug (RLD): an ANDA must designate an RLD from the NMPA catalogue; choosing wrongly invalidates the application.
- Bioequivalence (BE) study: chemical generics generally need a BE study at a qualified site, in GCP compliance.
- Patent declarations: applicants must make one of four declarations (P1: no listed patent; P2: patent expired; P3: will market after expiry; P4: patent invalid or not infringed). P4 triggers the patent-challenge procedure.
- First-generic exclusivity: the first generic to successfully challenge the originator's patent and win approval gains a 12-month market exclusivity during which CDE will not approve other same-product generics.
Cross-border registration
- Import registration: a drug marketed abroad must submit complete foreign R&D, manufacturing and clinical data and undergo registration inspection, including overseas on-site GMP inspection.
- Use of MRCT data: multi-regional clinical trial data from China can support a China NDA, subject to sufficiency and representativeness of the Chinese population.
- License-in evaluation: in licensing deals we conduct legal due diligence on registration feasibility, data gaps and timelines for the target drug in China.
- China IND supporting foreign filings: strategic use of China IND data to support submissions to FDA, EMA and others.
How we help
- Registration strategy: design the optimal classification, route and accelerated-pathway combination at project initiation.
- Legal review of filings: review the legal portions of IND/NDA/ANDA submissions (patent declarations, MAH information, contract manufacturing, informed consent).
- Regulatory communication: prepare for and attend CDE meetings on strategy, trial design and data requirements.
- PAI response: full legal support before and during registration inspection, including defect remediation and risk assessment.
- Post-approval change management: navigate registration procedures for formula, process, site and MAH changes.